LSX World Congress Europe
March 25, 2026
Lisbon, Portugal
Bioxodes' CEO Marc Dechamps will be attending the LSX World Congress Europe from 25 -26 March, 2026. Reach out to us if you want to connect during the event!
About us
Bioxodes
Bioxodes’ innovative pipeline is led by our BIOX-101 clinical-stage program for the prevention of thrombosis and neuroinflammation in intracerebral hemorrhage (ICH). We are also preparing BIOX-101 for a Phase 2 trial in ischemic stroke.
BIOX-101’s powerful dual mode of action inhibits the activation of neutrophils – the first responders of the immune system – and the release of the neutrophil extracellular traps (NETs). It also inhibits Factors XIa and XIIa of the intrinsic coagulation pathway, exerting a powerful anticoagulant effect. Crucially, it does so without increasing bleeding risk.
In parallel to its programs in stroke, Bioxodes is developing a pipeline of drug candidates to treat chronic thrombo-inflammatory and inflammatory diseases, leveraging BIOX-101’s inhibitory effect on the formation of the NETs.
BIOX-101 is our breakthrough lead candidate, designed to prevent secondary damage in intracerebral hemorrhage (ICH), a condition with significant unmet medical need. BIOX-101 is preparing for a potentially pivotal Phase 2b trial and has received Orphan Drug Designation in Europe and the U.S. for ICH. It is also on track for a Fast Track filing with the FDA and PRIME application in Europe.
video testimonial
Prof Robin Lemmens, a world-renowned stroke expert, shares his findings as the lead Investigator of the current Phase 2a trial for BIOX-101.
In this short video, recorded with Bioxodes’ leadership, he highlights: BIOX-101 was safe in ICH patients, with no increase in hematoma volume—“the finding that struck me most.” Being able to administer BIOX-101 safely while helping prevent secondary thrombosis is “very, very important.” Edema data were promising; limiting edema expansion is a key driver of better outcomes. Watch the clip to learn more. The full webinar can be found on the investor page.
Product
All products-
![]()
BIOX-101
First-in-class clinical-stage therapeutic to treat intracerebral hemorrhage, an often lethal disease with no approved treatment.
Read more -
![]()
Pipeline
Innovative pipeline targeting multiple thrombo-inflammatory indications and with ambitious discovery program.
Read More -
![]()
Clinical trials
Launching a potentially registrational Phase 2b trial for BIOX-101. Considering a Phase 2 trial for ischemic stroke.
Read More
Advisory Board
All Key Opinion Leaders-
Read more
Robin Lemmens , M.D.
Leuven, Belgium
-
Read more
Rustam Al-Shahi Salman , MA MB BChir PhD FRCP Edin FHEA FESO
Edinburgh, United Kingdom
-
Read more
Matthias Endres , M.D.
Berlin, Germany
-
Read more
David Seiffge , M.D.
Bern, Switzerland
-
Read more
Charlotte Cordonnier , M.D.
Lille, France
-
Read more
Denis Vivien , Ph.D
Caen, France
-
Read more
Cedric Hermans , M.D, Ph.D, FRCP (Lon, Edin)
Brussels, Belgium
-
Read more
Ashkan Shoamanesh , M.D.
Hamilton, Canada
-
Read more
Magdy Selim , M.D., PhD.
Boston, United-States
Recents News
BioEurope Spring 2026
March 23, 2026
Lisbon, Portugal
Bioxodes' CEO Marc Dechamps will be attending BioEurope Spring from March 23 - 25 to discuss Bioxodes latest developments. Reach out to us if you want to meet!
European Neuroscience Innovation Forum organized by Sachs Associates
March 03, 2026
Zurich, Switzerland
Our CEO Marc Dechamps will talk about Bioxodes’ groundbreaking work in stroke and how it contributes to brain health progress at the Sachs Associates First European Neuroscience Innovation Forum on 3 March in Zurich. Marc will take part in the “Health Span & Brain Health Panel: Putting Together the Pieces” – together with a distinguished line-up of investors and biotech experts: Anne Marije van Harten, Investment Director, Apollo Health Ventures, Yury Kukushkin, Investment Partner, Hevolution, Dani Bach, Managing Partner, Limani Partners, Jyothis George, Chief Medical Officer, NodThera, Inc. and Klaus Dugi, CEO, Vandria SA. With Marc at the event will be Philippe Monteyne, Chairman of the Board. At 11:00 AM CET, Marc will present Bioxodes, and our lead candidate, BIOX-101, to treat intracerebral hemorrhage (ICH). The 10-minute presentation will take place in room Berne - Track A.
Mapping Rare Disease in 2026, report by Stifel
February 18, 2026
Bioxodes appears as one of the 150 biotech companies in the “Mapping Rare Disease in 2026” report by Stifel Financial Corp. This comprehensive study is a valuable contribution, which will help raise awareness for diseases such as stroke. “Bioxodes exemplifies using a rare, acute condition to validate a novel therapeutic approach with broad potential,” the report says. “By starting with an orphan disease, Bioxodes aims to de-risk a platform that could address both rare and common conditions.” Stifel is a multinational independent investment bank and financial services company. Bioxodes’ lead candidate BIOX-101 targets a particularly deadly type of stroke: intracerebral hemorrhage (ICH). While responsible for only 15% of stroke cases, the disease claims 40% of all stroke-related deaths. Currently, no marketed treatment is available for these patients. That is why Bioxodes is using disruptive science to develop a therapeutic with breakthrough potential.
Investors
Invest in us
Bioxodes is a Belgian private company, founded in 2013. The Company has received fundings from both the public and private investors.
